Table 3.
The antibiotic susceptibility testing results of 32 EAEC isolates
| Antibiotic | Total EAEC, N (%)
|
ESBL producing EAEC, N (%)
|
||||
|---|---|---|---|---|---|---|
| R | I | S | R | I | S | |
| Gentamicin | 10 (31.2) | 0 | 22 (68.8) | 6 (26.1) | 0 | 17 (73.9) |
| Amikacin | 4 (12.5) | 1 (3.1) | 27 (84.4) | 3 (13) | 1 (4.3) | 19 (82.6) |
| Ciprofloxacin | 6 (18.8) | 1 (3.1) | 25 (78.1) | 5 (21.7) | 1 (4.3) | 17 (73.9) |
| Cefoxitin | 5 (15.6) | 0 | 27 (84.4) | 0 | 0 | 23 (100) |
| Ceftazidime | 17 (53.1) | 4 (12.5) | 11 (34.4) | 12 (52.2) | 3 (13) | 8 (34.8) |
| Cefotaxime | 26 (81.3) | 0 | 6 (18.8) | 20 (87) | 0 | 3 (13) |
| Cefpodoxime | 26 (81.3) | 0 | 6 (18.8) | 20 (87) | 0 | 3 (13) |
| Cefteriaxon | 26 (81.3) | 1 (3.1) | 5 (15.6) | 21 (91.3) | 0 | 2 (8.7) |
| Ampicillin | 32 (100) | 0 | 0 | 23 (100) | 0 | 0 |
| Meropenem | 3 (9.4) | 3 (9.4) | 26 (81.3) | 1 (4.3) | 2 (8.7) | 20 (87) |
| Imipenem | 0 | 0 | 32 (100) | 0 | 0 | 23 (100) |
| Tetracycline | 15 (46.9) | 0 | 17 (53.1) | 7 (30.4) | 0 | 16 (69.6) |
| Trimethoprim/sulfamethoxazole | 32 (100) | 0 | 0 | 23 (100) | 0 | 0 |
| Azithromycin | 25 (78.1) | 0 | 7 (21.9) | 18 (78.3) | 0 | 5 (21.7) |
Abbreviations: EAEC, enteroaggregative Escherichia coli, ESBL, extended-spectrum β-lactamase.